Filing Details
- Accession Number:
- 0000950170-25-081935
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-06-04 20:34:33
- Reporting Period:
- 2025-06-02
- Filing Date:
- 2025-06-04
- Accepted Time:
- 2025-06-04 20:34:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1088856 | Corcept Therapeutics Inc | CORT | Pharmaceutical Preparations (2834) | 770487658 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1817838 | Douglas Joseph Lyon | C/O Corcept Therapeutics Incorporated 101 Redwood Shores Parkway Redwood City CA 94065 | See Remarks | No | No | No | No |
Transaction Summary
| Sold: | 5,000 shares | Avg. Price: $78.04 | Total Value: $390,218.44 |
| Number of Shares After Transactions: | 10,066 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-06-02 | 5,000 | $13.56 | 14,009 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-06-02 | 4,438 | $77.97 | 9,751 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-06-02 | 562 | $78.65 | 9,009 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-06-02 | 749 | $71.68 | 9,758 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2025-06-02 | 749 | $0.00 | 10,507 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2025-06-03 | 441 | $71.68 | 10,066 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2025-06-02 | 5,000 | $0.00 | 5,000 | $13.56 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 41,571 | 2030-02-07 | No | 4 | M | Direct |
Footnotes
- Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.56 to $78.55 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.57 to $78.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025.
- In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
- These shares were withheld by the Issuer in order to satisfy certain withholding obligations in connection with the issuance of share upon the vesting of restricted stock units.
- The closing price on June 2, 2025 was used to calculate the withholding obligation.
- Fully exercisable.
Billionaire Hedge Funds
